Self-amplifying mRNA (SAM) Vaccine Platform
Compared with traditional vaccines, nucleic acid vaccines have the advantages of easy preparation, cross-protection of allogeneic strains, convenient storage and transportation, and the like. As a professional and experienced vaccine researcher, Creative Biolabs conducts extensive and in-depth research on various types of vaccines, especially in the field of nucleic acid vaccines. In addition to the research on DNA vaccines, our proven self-amplifying mRNA platform is helping global vaccine researchers better perform their research tasks.
Background
The advent of the genetic era has opened the curtain for nucleic acid vaccines. Initially, most of the scientists' research on nucleic acid vaccines focused on DNA vaccines, but in 1996 Boczkowski found that murine dendritic cells can present antigens after being pulsed by OVA mRNA, which promotes the development of cell-based immunotherapy. Recently, mRNA-based vaccines have also been extensively studied. Such vaccines are not only capable of inducing humoral and cellular immunity like viral vector vaccines and DNA vaccines, but also avoiding the induction of anti-vector immunity and without the risk of genome integration into the host genome. In addition to this, the expression of the antigen caused by the inoculation of mRNA is transient, and thus there are no concerns of T cell exhaustion due to continuous exposure of the antigen.
Self-amplifying mRNA Vaccine (SAM)
RNA vaccines can be divided into traditional mRNA-based vaccines and self-amplifying mRNA (SAM) vaccines. Their basic principle is to use the host cell's transcription system to produce target antigens to stimulate adaptive immunity. The difference is that the former contains only the target antigen gene and cannot replicate itself; the latter encodes the engineered genome of the RNA virus, which contains the virus's non-structural protein gene and the antigen gene that replaces the structural protein gene. The resulting RNA can express antigenic genes at a high level due to the amplification effect of the RNA template, and these replicons cannot produce infectious virions because they delete the gene of the structural protein of the virus, and cannot spread to the adjacent cells.
Fig.1 Schematic for the self-amplifying mRNA vaccine.
Features of Our Self-amplifying mRNA Vaccine Platform
- Robust immunogenicity in inducing both humoral and cellular immune responses
- Intrinsic adjuvant properties
- Relatively low cost
- Easy production process
- Preferable safety
- Multiple advanced delivery systems
- Less vaccine preparation time
Services of Self-amplifying mRNA Vaccine Development
- SAM vaccine design
- Synthesis of SAM vaccine
- Optimization of SAM vaccines
- Preclinical evaluation of SAM vaccine
Creative Biolabs has more than 10 years of experience in the field of vaccines. Our professional R&D team and extensive practical experience make us always able to provide our customers with the most satisfactory products and services. As your reliable vaccine research partner, if you have a need for vaccine research, please contact us immediately.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
